Liao Hailing, Chang Xiaoyan, Hou Xiaorong, Zhang Fuquan
Department of Radiation Oncology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.
Department of Radiation Oncology, Pengshui Miao Tujia Autonomous County People's Hospital, Chongqing 409600, P.R. China.
Oncol Lett. 2025 May 16;30(1):349. doi: 10.3892/ol.2025.15095. eCollection 2025 Jul.
Cervical cancer metastasis to the pancreas is rare, and the clinical manifestations are variable and contingent upon the location of the metastasis. Consequently, certain patients may be overlooked due to the absence of overt clinical symptoms. Nevertheless, there is no universally accepted treatment protocol for such patients. The present report describes a case of a 64-year-old woman with stage IIIB cervical squamous cell carcinoma (International Federation of Gynecology and Obstetrics 2009) who received definitive chemoradiation in March 2018 [intensity modulated radiation therapy (IMRT) + weekly paclitaxel + brachytherapy]. After 6 years, pancreatic metastasis was confirmed by MRI/PET-CT and endoscopic ultrasonography-guided fine-needle aspiration biopsy. Between January and May 2024, the patient underwent six cycles of paclitaxel/carboplatin/bevacizumab/programmed cell death protein 1 inhibitor therapy followed by IMRT (45 Gy with 55 Gy boost). Post-treatment imaging revealed a partial response (lesion reduction from 45×30 mm to 32×20 mm). As of November 2024, the latest data indicated that the patient was disease-free on pembrolizumab maintenance. Furthermore, a systematic review of 14 related cases described in previous studies to analyze the characteristics of metastatic pancreatic cancer (mPC) is presented. In total, 14 publications were identified for systematic review. Among these patients, 7 had squamous cell carcinoma. The median age of the patients at the time of initial diagnosis was 49.8 years, and the mean interval between the identification of the primary tumor and metastasis was 46 months. Several clinical manifestations were observed depending on the site of metastasis. Endoscopic ultrasonography-guided fine-needle aspiration was revealed as one of the most effective methods for diagnosing mPC. In conclusion, there is currently no consensus regarding subsequent treatment plans. Pancreatic metastases originating from cervical cancer are infrequent and necessitate careful consideration along with individualized treatment approaches.
宫颈癌转移至胰腺较为罕见，其临床表现多样，取决于转移部位。因此，部分患者可能因缺乏明显临床症状而被漏诊。然而，对于这类患者尚无普遍接受的治疗方案。本报告描述了一例64岁患有IIIB期宫颈鳞状细胞癌（2009年国际妇产科联盟分期）的女性患者，她于2018年3月接受了根治性放化疗[调强放射治疗（IMRT）+每周紫杉醇+近距离放射治疗]。6年后，通过MRI/PET-CT和内镜超声引导下细针穿刺活检确诊为胰腺转移。在2024年1月至5月期间，该患者接受了六个周期的紫杉醇/卡铂/贝伐单抗/程序性细胞死亡蛋白1抑制剂治疗，随后进行IMRT（45 Gy，追加剂量至55 Gy）。治疗后影像学检查显示部分缓解（病灶从45×30 mm缩小至32×20 mm）。截至2024年11月，最新数据表明患者在接受帕博利珠单抗维持治疗期间无疾病进展。此外，还对先前研究中描述的14例相关病例进行了系统回顾，以分析转移性胰腺癌（mPC）的特征。总共确定了14篇出版物进行系统回顾。在这些患者中，7例为鳞状细胞癌。患者初次诊断时的中位年龄为49.8岁，原发肿瘤确诊与转移之间的平均间隔时间为46个月。根据转移部位观察到了几种临床表现。内镜超声引导下细针穿刺被证明是诊断mPC最有效的方法之一。总之，目前对于后续治疗方案尚无共识。宫颈癌引起的胰腺转移罕见，需要仔细考虑并采取个体化治疗方法。
